Skip to content

Released Aug 3, 2022, after the close

10-Q filed Aug 3, 2022, 34 days after period end · 0000950170-22-014236

Q2 2022 · 10-Q
Revenue$18.55M+38.3% vs Q2 2021+0.7% vs Q1 2022
Net Income-$76.11MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.79N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$83,109,000N/M
Operating Cash Flowderived-$53,159,000N/M
Free Cash Flowderived-$63,288,000N/M
Margins · derived
Operating margin-448.1%−99.3 pt vs Q2 2021
Net margin-410.3%+0.8 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$18.55M$13.41M$5.47M$2.82M
Net Income-$76.11M-$55.13M-$28.07M-$23.48M
EPS Diluted-$0.79-$0.58-$0.35-$0.36

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR